Niigata, Japan - The research group of Professor Kamimura in Niigata University have reported the usefulness of a drug repositioning method based on the gene expression alteration in the chimeric mice with humanized hepatocytes and revealed that letrozole, which is used to treat breast cancer, is effective in suppressing the progression of liver fibrosis. “Letrozole ameliorated MCD- and CCl4-induced liver fibrosis by suppressing the Yap-Ctgf pathway by partially modifying the expressions of Hsd17b13 and Cyp26a1, which reduced retinoic acid level in the hepatocytes”, says Prof. Kamimura.
He concluded that letrozole might be repurposed for the treatment of liver fibrosis as its off-target effect, and that gene expression-based screening using a PXB-mouse is effective to identify the drug specific efficacy and off-target effect of the repurposing drugs for the hepatocytes in the human liver.
Journal of Gastroenterology
Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression
Article Publication Date